Kester J E, Gasiewicz T A
Biochim Biophys Acta. 1987 Aug 13;925(2):109-16. doi: 10.1016/0304-4165(87)90099-7.
These studies investigated the effects of various serine proteinase inhibitors and substrates on the TCDD-binding capacity of the rat hepatic Ah receptor. TCDD binding to the Ah receptor was inhibited by serine proteinase inhibitors phenylmethylsulfonyl fluoride (PMSF), tosyl-lysine chloromethyl ketone (TosLysCH2Cl), tosylamide-phenylethyl chloromethyl ketone (TosPheCH2Cl) and substrates tosyl-L-arginine methyl ester (TosArgOMe) and D-tryptophan methyl ester (TrpOMe). The order of potency was TosPheCH2Cl greater than TosLysCH2Cl much greater than PMSF approximately equal to TosArgOMe approximately equal to TrpOMe. Reactivity of the chloromethyl ketones with sulfhydryl groups was suggested by their steep inhibition curves above the concentration of nonprotein sulfhydryl groups, and the partial mitigation of inhibition by 1 mM dithiothreitol. Inhibition by these reagents was irreversible, while that by TosArgOMe and TrpOMe was completely reversible by gel filtration. The mechanism of inhibition by TosArgOMe and TrpOMe was formally competitive, with inhibition constants similar to those reported in steroid hormone receptor systems. Neither inhibitors nor substrates displaced previously bound TCDD.
这些研究调查了各种丝氨酸蛋白酶抑制剂和底物对大鼠肝脏芳烃(Ah)受体与2,3,7,8-四氯二苯并-p-二恶英(TCDD)结合能力的影响。丝氨酸蛋白酶抑制剂苯甲基磺酰氟(PMSF)、甲苯磺酰赖氨酸氯甲基酮(TosLysCH2Cl)、甲苯磺酰胺-苯乙基氯甲基酮(TosPheCH2Cl)以及底物甲苯磺酰-L-精氨酸甲酯(TosArgOMe)和D-色氨酸甲酯(TrpOMe)均可抑制TCDD与Ah受体的结合。其效力顺序为:TosPheCH2Cl>TosLysCH2Cl>>PMSF≈TosArgOMe≈TrpOMe。氯甲基酮在非蛋白质巯基浓度以上呈现陡峭的抑制曲线,且1 mM二硫苏糖醇可部分减轻抑制作用,这表明氯甲基酮与巯基具有反应活性。这些试剂的抑制作用是不可逆的,而TosArgOMe和TrpOMe的抑制作用通过凝胶过滤可完全逆转。TosArgOMe和TrpOMe的抑制机制为形式上的竞争性抑制,其抑制常数与类固醇激素受体系统中报道的相似。抑制剂和底物均不能取代先前结合的TCDD。